Overview

B-cell CLL/lymphoma 10 (BCL10) is a gene that encodes a protein that contains a caspase recruitment domain (CARD). The protein functions in the induction of apoptosis and activation of NF-KappaB. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift insertions and deletions, and in-frame deletions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.

BCL10 is altered in 0.48% of all cancers with colon adenocarcinoma, diffuse large B-cell lymphoma, not otherwise specified, endometrial endometrioid adenocarcinoma, lung adenocarcinoma, and mantle cell lymphoma having the greatest prevalence of alterations [3].

The most common alterations in BCL10 are BCL10 Mutation (0.27%), BCL10 Loss (0.09%), BCL10 Amplification (0.04%), BCL10 R58Q (0.02%), and BCL10 L174* (0.04%) [3].

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.